Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82335 | 0.86 | NAMPT (0.65) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL3458122 | 0.85 | NAMPT (0.64) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL82565 | 0.85 | LMNA (0.52) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL83006 | 0.84 | ACHE (0.57) | CYP3A4CYP2C9LMNAPTAFRCYP1A2 | |
| SCHEMBL82962 | 0.84 | C3AR1 (0.54) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL3458648 | 0.83 | NAMPT (0.61) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL5400171 | 0.83 | NAMPT (0.59) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL81910 | 0.82 | PTAFR (0.50) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL81394 | 0.81 | PTAFR (0.49) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL3067194 | 0.81 | LMNA (0.48) | NAMPTCYP3A4CYP2C9LMNAPTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | claimed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | claimed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | claimed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | disclosed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | disclosed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | NAMPT 385/4885CYP3A4 1626/4885CYP2C9 2009/4885 |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | ALK, TYMP, ANXA1 | NAMPT 346/4885CYP3A4 1507/4885CYP2C9 1795/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | NAMPT 2/4885CYP3A4 905/4885CYP2C9 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.